和邦生物(603077.SH):武駿玻璃增資擴股引進投資者 增資金額4.73億元
格隆匯6月9日丨和邦生物(603077.SH)公佈,公司的全資子公司四川武駿特種玻璃製品有限公司(“武駿玻璃”)通過增資擴股方式引進投資者,增資金額為4.73億元。
為實現公司專注、專業化的發展戰略,公司擬定了光伏組件及光伏玻璃項目的發展計劃,需增加資本金投入。現武駿玻璃通過增資擴股方式引進投資者,公司放棄對武駿玻璃增資所享有的優先認購權,武駿玻璃於近日與投資者簽訂了《股權投資協議書》。本次增資完成後,武駿玻璃的註冊資本將由4億元增加至4.5261億元,公司的持股比例將由100%變更為88.38%,武駿玻璃仍為公司控股子公司,新引入的投資者持股比例為11.62%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.